<DOC>
	<DOCNO>NCT00800683</DOCNO>
	<brief_summary>determine safety , efficacy tolerability BI 1356 versus placebo</brief_summary>
	<brief_title>Safety Efficacy Type 2 Diabetic Patients With Severe Chronic Renal Impairment , 5 mg BI 1356 ( Linagliptin ) v . Placebo , Insulin Background Inclusive</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Male female patient type 2 diabetes glomerular filtration rate ( GFR ) &lt; 30 ml/min , chronic dialysis . Insufficient glycemic control ( hemoglobin A1c ( HbA1c ) 7.0 % 10.0 % ) Age 18 old 80 year Exclusion criterion : Treatment anti diabetic drug insulin and/or sulphonylurea within 3 month prior inform consent Myocardial infarction , stroke transient ischemic attack ( TIA ) within 6 month prior inform consent Unstable acute congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>